Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05025813
Title Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE)
Acronym DESQUAMATE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Queensland Health
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.